MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Chloropyramine hydrochloride

CAS No. : 6170-42-9

MCE 站：Chloropyramine hydrochloride

产品活性：Chloropyramine hydrochloride 是一种组胺受体 H1 (histamine receptor H1) 拮抗剂，它也能抑制 VEGFR-3 和 FAK 的生化功能。

研究领域：Protein Tyrosine Kinase/RTK  |  Immunology/Inflammation  |  GPCR/G Protein  |  Neuronal Signaling

作用靶点：FAK  |  Histamine Receptor  |  VEGFR

In Vitro: BT474 cells are highly sensitive to Chloropyramine hydrochloride (compound 1) treatment, whereby 1 ?M concentrations cause a 40% reduction of viability after 48 h of treatment. It is found that at 1 ?M concentrations of Chloropyramine hydrochloride, viability of control MCF7-pcDNA3 cells is significantly higher than the viability of MCF7-VEGFR-3 cells (P<0.01) and at 10 ?M concentration this difference reaches twofold (P<0.001). In the BT474 cells treatment with Chloropyramine hydrochloride also leads to a concentration-dependent decrease of cell proliferation. When treatment with Chloropyramine hydrochloride is continued for 48 h, the breast cancer cells that overexpressed VEGFR-3 undergo apoptosis. This effect is dose-dependent, with 10 ?M Chloropyramine hydrochloride inducing apoptosis in more than 60% of BT474 cells. In our model cell lines MCF7-pcDNA3 and MCF7-VEGFR-3, treatment with 10 ?M Chloropyramine hydrochloride for 48 h leads to a 4-fold increase in apoptotic cell death in the cell line that overexpressed VEGFR-3 (18% versus 76 % respectively).

In Vivo: Chloropyramine hydrochloride causes a dramatic reduction of tumor growth in both model systems whereby the tumor size in the treated groups is approximately 20% of the tumor size in vehicle control groups. Doxorubicin administered at 3 mg/kg causes approximately 60% reduction of tumor growth, but has no effect on tumor growth at 0, 3 mg/kg. In contrast, there is a modest effect of Chloropyramine hydrochloride alone (50% reduction of tumor growth). The low-dose combination of Chloropyramine hydrochloride and doxorubicin has a prolonged anti-tumor effect (85% reduction of tumor growth) that is greater than either drug alone.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  Neuronal Signaling Compound Library  |  Protein Tyrosine Kinase Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Endocrinology Compound Library  |  Cytoskeleton Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Bevacizumab  |  Sunitinib  |  Semaxinib  |  SU 5402  |  Histamine  |  PD173074  |  PF-573228  |  5Z-7-Oxozeaenol  |  Cediranib  |  SAR131675  |  Y15  |  SU6656  |  Clemastine fumarate  |  Gandotinib  |  GW806742X  |  Tanshinone IIA  |  PF-03814735  |  Amitriptyline hydrochloride  |  Astemizole  |  Fexofenadine hydrochloride  |  Osthole  |  Terfenadine  |  Fangchinoline  |  Famotidine  |  NVP-TAE 226  |  Diphenhydramine hydrochloride  |  Levocetirizine dihydrochloride  |  Perphenazine  |  Vatalanib dihydrochloride  |  Loratadine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。